Related Experiment Video
Updated: May 26, 2026
06:27
Transcutaneous Microcirculatory Imaging in Preterm Neonates
Published on: December 31, 2015
Topical propranolol therapy for infantile hemangiomas
1Department of Dermatology and Allergic Diseases, University of Ulm, Ulm, Germany. karin.rapp@ilm.uni-ulm.de
Pediatric Dermatology
|December 7, 2011
Summary
Topical propranolol ointment effectively treats superficial infantile hemangiomas, showing significant regression and growth cessation with minimal side effects. This localized therapy offers a well-tolerated alternative for infants, including preterm babies.
Area of Science:
- Dermatology
- Pediatrics
- Pharmacology
Background:
- Infantile hemangiomas are common benign vascular tumors in infants.
- Systemic propranolol is an established treatment but can have side effects.
- Local application of propranolol may offer a targeted and safer alternative.
Purpose of the Study:
- To evaluate the efficacy and tolerability of topical propranolol ointment for superficial infantile hemangiomas.
- To assess treatment outcomes in different age groups and hemangioma subtypes.
- To determine if local propranolol is effective in proliferative and involuting phases.
Main Methods:
- A study involving 45 children with 65 superficial hemangiomas treated with 1% propranolol ointment twice daily.
- Clinical photographs and ultrasound were used for assessment.
- Treatment outcomes were evaluated based on regression, growth cessation, and side effects.
Main Results:
- Regression was observed in 59% and growth cessation in 26% of hemangiomas treated during the proliferative phase.
- No response or deeper component proliferation occurred in 15% of cases.
- Topical propranolol was well-tolerated with no observed side effects, even in preterm infants.
Conclusions:
- Topical propranolol 1% ointment is a beneficial and well-tolerated treatment for superficial infantile hemangiomas.
- The treatment shows efficacy in inducing regression and halting growth, particularly in younger infants.
- Local propranolol offers a safe therapeutic option with minimal systemic absorption concerns.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...